SCHEMBL2111644

SCHEMBL2111644

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc(C2CC2c2ccc(NS(C)(=O)=O)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.69
KDM1A O60341 7/20 0.39
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
NR3C2 P08235 1/20 0.35
PIP4K2A P48426 2/20 0.35
PIP4K2B P78356 2/20 0.35
PIP4K2C Q8TBX8 1/20 0.35
PDPK1 O15530 1/20 0.35
TDP2 O95551 1/20 0.34
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
JAK2 O60674 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
NR2F2 P24468 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3421761 0.88 CYP3A4 (0.63) CYP3A4KDM1AMAOAMAOBNR3C2
SCHEMBL2112242 0.86 CYP3A4 (0.52) CYP3A4KDM1AMAOAMAOBNR3C2
SCHEMBL726323 0.84 CYP3A4 (0.64) CYP3A4KDM1ANR3C2PDPK1BRD4
SCHEMBL3477314 0.83 CYP3A4 (0.49) CYP3A4KDM1AMAOAMAOBNR3C2
SCHEMBL2111363 0.82 CYP3A4 (1.00) CYP3A4KDM1AMAOAMAOBNR3C2
SCHEMBL2112475 0.82 CYP3A4 (1.00) CYP3A4KDM1AMAOAMAOBNR3C2
SCHEMBL725581 0.82 CYP3A4 (1.00) CYP3A4KDM1AMAOAMAOBNR3C2
SCHEMBL1543239 0.79 CYP3A4 (0.68) CYP3A4NR3C2PIP4K2APIP4K2BPIP4K2C
SCHEMBL1543237 0.79 CYP3A4 (0.68) CYP3A4NR3C2PIP4K2APIP4K2BPIP4K2C
SCHEMBL1542619 0.78 CYP3A4 (0.67) CYP3A4LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158803-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-04-17 US claimed
US-20100272677-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS LEE EUN KYUNG 2010-10-28 US claimed
US-8158803-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-04-17 US disclosed
US-20100272677-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS LEE EUN KYUNG 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272677-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, RRM2B CYP3A4 417/4885KDM1A 1567/4885MAOA 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.